fda d.i.s.c.o. burst edition: fda approval of trodelvy (sacituzumab govitecan-hziy) for hr-positi...
Published 5 months ago • 70 plays • Length 4:01Download video MP4
Download video MP3
Similar videos
-
4:41
fda approved akt inhibitor for patients with advanced hr-positive breast cancer
-
6:01
sacituzumab govitecan given accelerated fda approval for advanced urothelial cancer
-
1:00:38
sickle cell disease: a spotlight on women
-
7:35
fda approval for abemaciclib
-
9:00
fda d.i.s.c.o.: two approvals for alk-positive non-small cell lung cancer
-
3:59
sacituzumab govitecan increases pfs for hr /her2- metastatic breast cancer
-
5:25
her2climb fda approval
-
19:23
breast implants & health problems dr. ed melmed on know the cause
-
30:41
what makes triple negative breast cancer aggressive?
-
3:55
oncopower trodelvy (sacituzumab govitecan-hziy) and what are its side effects? | oncopower
-
5:07
tropics-02: sacituzumab govetican improves pfs versus physicians choice for hr /her2- mbc
-
3:50
overview of recent fda approvals for metastatic hr breast cancer
-
7:21
fda approval of ribociclib for metastatic breast cancer
-
11:00
fda approval in her2 breast cancer, priority review in nsclc, and more
-
6:00
fda d.i.s.c.o.: niraparib in ovarian cancer
-
10:55
fda approvals in cinv and her2 breast cancer, priority review in myelofibrosis, and more
-
3:14
fda advises health care providers about breast implants and alcl
-
4:17
debu tripathy, md, discusses recent fda approvals and her2 metastatic breast cancer management
-
6:48
fda approval in prostate cancer, phase iii data in breast cancer, and more
-
7:26
sacituzumab govitecan increases pfs for hr /her2‐ advanced breast cancer patients
-
2:07
the impact of updated fda regulation on breast density notification | uw medicine